PSA Screening for HIM Act
Take action
Record your position on this measure.
Create an account to take a stance, submit a written position, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Overview
This bill, the Prostate-Specific Antigen Screening for High-risk Insured Men Act, requires private health insurance plans to cover prostate cancer screenings for men age 40 and older who are considered high-risk, including African-American men and those with a family history of the disease. Plans must provide this coverage without requiring patients to pay extra through cost-sharing like deductibles or co-pays. The bill aims to improve early detection rates and reduce mortality from prostate cancer, particularly among groups with a higher risk.
Key provisions
- Requires private health insurance plans to cover prostate cancer screenings for men age 40 and older.
- Specifically includes African-American men and men with a family history of prostate cancer as high-risk individuals.
- Prohibits cost-sharing (deductibles, co-pays) for these screenings.
- Defines ‘family history’ of prostate cancer to include various relatives with the disease or related cancers.
- References the U.S. Preventive Services Task Force recommendations for screening.
- Clarifies the effective date for coverage as January 1, 2026.
- Addresses the need for research on screening African-American men at younger ages.
- Establishes a rule of construction allowing plans to provide additional coverage beyond the Task Force recommendations.
Who is affected
- Private health insurance companies
- Individuals with private health insurance
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
38 on record
Primary sponsor
Cosponsors
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours